Phase II randomized, open-label study of cetuximab (Cet) and bevacizumab (Bev) in combination with paclitaxel (P) and carboplatin (C) in patients with stageIII/IV non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Bonomi, P. D. [1 ]
Mace, J. [1 ]
Mandanas, R. D. [1 ]
Min, M. [1 ]
Zhang, Y. [1 ]
Rowinsky, E. [1 ]
Youssoufian, H. [1 ]
机构：
[1] Rush Univ, Ctr Med, Chicago, IL 60612 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8046
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Randomized Phase II Study of Paclitaxel and Carboplatin or Vinorelbine in Advanced Non-small Cell Lung Cancer
    Jahnke, Kristoph
    Keilholz, Ulrich
    Lueftner, Diana
    Thiel, Eckhard
    Schmittel, Alexander
    ANTICANCER RESEARCH, 2011, 31 (01) : 317 - 323
  • [32] Phase Ib/II study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC).
    McKeage, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 389S - 389S
  • [33] A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC)
    Socinski, M. A.
    Saleh, M. N.
    Trent, D. F.
    Dobbs, T. W.
    Zehngebot, L. M.
    Levine, M. A.
    Bordoni, R.
    Stella, P. J.
    ANNALS OF ONCOLOGY, 2009, 20 (06) : 1068 - 1073
  • [34] Randomized, open-label, phase III study of pemetrexed plus carboplatin followed by maintenance pemetrexed (Arm A) versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab (Arm B) in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).
    Zinner, Ralph
    Ross, Helen J.
    Weaver, Robert
    Govindan, Ramaswamy
    Holden, Viran R.
    Chowhan, Naveed Mahfooz
    Beck, J. Thaddeus
    Waterhouse, David Michael
    Modiano, Manuel
    Rao, Vijay Phooshkooru
    Liu, Jingyi
    Koustenis, Andrew
    Melemed, Symantha
    Guba, Susan C.
    Ortuzar, Waldo Feliu
    Desaiah, Durisala
    Spigel, David R.
    Obasaju, Coleman K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] A phase IB trial of iniparib (BSI-201) in combination with carboplatin (C)/paclitaxel (P) in patients with non-small cell lung cancer (NSCLC).
    Mita, A. C.
    Mita, M. M.
    Rocha, C.
    Bradley, C. R.
    Sarantopoulos, J.
    O'Rourke, P.
    Gadgeel, S. M.
    Wozniak, A. J.
    Heath, E. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin in advanced non-small cell lung cancer (NSCLC) patient.
    Joerger, Markus
    Von Pawel, Joachim
    Kraff, Stefanie
    Fischer, Juergen R.
    Eberhardt, Wilfried
    Gauler, Thomas Christoph
    Mueller, Lothar
    Reinmuth, Niels
    Reck, Martin
    Kimmich, Martin
    Mayer, Frank
    Kopp, Hans-Georg
    Behringer, Dirk M.
    Ko, Yon-Dschun
    Frueh, Martin
    Hilger, Ralf A.
    Roessler, Max
    Moritz, Berta
    Jaehde, Ulrich
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Phase I/II study of bortezomib in combination with carboplatin and bevacizumab as first line therapy in patients with advanced non-small cell lung cancer (NSCLC)
    Piperdi, Bilal
    Bradley, Kendra J.
    Bathini, Venu
    Zekos, Colleens M.
    Hanrahan-Boshes, Meredith
    Walsh, William V.
    CANCER RESEARCH, 2010, 70
  • [38] Safety analysis of a phase II randomized trial of carboplatin (C), paclitaxel (P), bevacizumab (B) with or without cixutumumab (CX) in patients (pis) with advanced nonsquamous, non-small cell lung cancer (NSCLC).
    Argiris, Athanassios
    Lee, Ju-Whei
    Leach, Joseph W.
    Schiller, Joan H.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [39] PHASE 1 STUDY OF IPILIMUMAB IN COMBINATION WITH PACLITAXEL/CARBOPLATIN IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
    Nokihara, Hihoshi
    Horinouchi, Hidehito
    Yagishita, Shigehiro
    Kitazono, Satoru
    Mizugaki, Hidenori
    Kanda, Shintaro
    Fujiwara, Yutaka
    Yamamoto, Noboru
    Iida, Mayumi
    Tokudome, Takuto
    Tamura, Tomohide
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S911 - S911
  • [40] Phase I dose-escalation study of sorafenib in combination with bevacizumab (B), paclitaxel (P), and carboplatin (C) for the treatment of advanced nonsquamous non-small cell lung cancer (NSCLC).
    Blumenschein, G. R.
    Molina, J. R.
    Lathia, C. D.
    Ong, T. J.
    Roth, D.
    Rajagopalan, P.
    Fossella, F. V.
    Kies, M. S.
    Marks, R. S.
    Adjei, A. A.
    Sundaresan, P. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345